AOD-9604 is a modified C-terminal fragment of human growth hormone (residues 176-191) originally developed as an anti-obesity drug candidate. Designed to isolate the lipolytic effect of growth hormone without the broader endocrine signal. Not FDA approved; clinical trial efficacy modest. Used at THE WELLNESS CO. as a layered adjunct within broader optimization protocols.
AOD-9604 stands for "Anti-Obesity Drug 9604" — the development designation given by Metabolic Pharmaceuticals (Australia), which originally developed the molecule as a candidate weight-loss agent in the early 2000s. Structurally, it is a 16-amino-acid synthetic peptide consisting of the C-terminal fragment of human growth hormone (residues 176-191) with an added N-terminal tyrosine.
The design intent was specific: growth hormone has many effects across the body — muscle, bone, glucose metabolism, IGF-1 production, somatic growth, and lipolysis (fat breakdown). The C-terminal fragment was identified in basic research as primarily responsible for the lipolytic effect. AOD-9604 isolates that segment, theoretically retaining the adipose-tissue effect while removing the broader endocrine consequences of full GH administration.
In animal models and early human studies, the molecule demonstrated lipolytic activity on adipose tissue without significantly elevating serum IGF-1 or producing GH-class effects on glucose metabolism. That biological premise is real. The clinical magnitude of effect was modest.
AOD-9604 is not FDA approved for any indication. Phase II clinical trials in human obesity, sponsored by Metabolic Pharmaceuticals, demonstrated modest weight-loss effects versus placebo — the molecule did not advance to FDA approval, and the company eventually ceased clinical development. Compounded AOD-9604 is currently used in off-label peptide protocols. We discuss the regulatory status and the modest, mixed clinical efficacy data with every AOD-9604 candidate before any prescription is written. Patients expecting pharmaceutical-scale weight loss from AOD-9604 will be disappointed; the data does not support that expectation.
AOD-9604 is not a primary weight-loss intervention at THE WELLNESS CO. It is used as a layered adjunct within broader hormone and metabolic optimization. The typical patient profile:
For patients who have not yet addressed hormone, insulin, thyroid, or lifestyle drivers, AOD-9604 is the wrong starting point. Adding a modest-effect adjunct on top of unaddressed primary drivers is not a sound clinical approach. We address the upstream first.
The CLARITY methodology evaluates the metabolic, hormonal, and lifestyle drivers of body composition. The 42-marker panel surfaces fasting insulin, HbA1c, full hormone profile, thyroid panel, lipid markers, hs-CRP, and the broader metabolic picture. Most patients with persistent fat gain have one or more clearly addressable upstream drivers.
For most patients, those drivers are where the work happens. Hormone optimization, insulin sensitivity correction, thyroid restoration, and lifestyle work produce the meaningful body-composition shifts. CJC-1295/Ipamorelin is often layered when GH-axis decline is documented. AOD-9604 enters specifically for patients whose protocol is otherwise stable but whose adipose-tissue response has plateaued — and for whom an adjunct lipolytic intervention is clinically reasonable.
Phase II trial data from Metabolic Pharmaceuticals showed modest weight-loss effects in obese subjects over 12-week to 24-week treatment periods versus placebo — effect sizes substantially smaller than what is seen with GLP-1 receptor agonists or surgical interventions. The drug did not advance to Phase III pivotal trials and was not pursued to FDA approval.
Patient-reported experience in clinical peptide practice varies. Some patients describe a meaningful adjunctive shift in body composition over an 8-12 week protocol; others describe minimal noticeable change. The patient who will be happy with AOD-9604 is the patient with realistic expectations about adjunctive effect size. The patient who expects substantial pharmaceutical-scale weight loss should look elsewhere — and we explicitly discuss that we do not prescribe GLP-1 medications as part of our methodology.
Baseline weight, waist circumference, and where available body composition analysis (DEXA, BIA). Re-evaluated at 8-12 weeks. The clinical question is whether the adjunct is producing a measurable shift; if not, the protocol is reassessed.
Fasting insulin, HbA1c, lipid panel, and the broader CLARITY metabolic markers re-tested at 8-12 weeks. AOD-9604 was specifically designed to avoid the glucose-tolerance effects of full GH, but we monitor regardless.
AOD-9604 was designed not to elevate IGF-1, and trial data supports that claim — but we measure it because the molecule originated from a GH fragment, and we verify rather than assume.
Patients with active malignancy. Pregnant or breastfeeding patients. Patients with severe untreated metabolic disease, untreated hypothyroidism, or untreated diabetes — those conditions are addressed first. Patients seeking AOD-9604 as a primary weight-loss intervention without supporting clinical context. We do not prescribe AOD-9604 as a standalone weight-loss solution; it is a layered adjunct only, used within a broader optimization protocol with realistic expectations about effect magnitude.
The most clinically sound combinations:
AOD-9604 is a 16-amino-acid synthetic peptide consisting of the C-terminal fragment of human growth hormone (residues 176-191) with an added N-terminal tyrosine. It was designed to retain the lipolytic (fat-burning) effects of the C-terminal portion of growth hormone while removing the effects on glucose metabolism, IGF-1 elevation, and somatic growth that come with full-length GH. In effect, it isolates one specific aspect of GH biology — the adipose-tissue effect — without the broader endocrine signal.
AOD-9604 is not FDA approved for any indication. The molecule was originally developed by Metabolic Pharmaceuticals as an anti-obesity drug candidate. Phase II clinical trials in obesity demonstrated modest weight-loss effects versus placebo — the molecule did not advance to FDA approval. Compounded use is off-label. We are transparent about the regulatory status and the modest, mixed clinical efficacy data with every AOD-9604 candidate before any prescription.
AOD-9604 is most appropriate as an adjunct within a broader hormone- and metabolic-optimization protocol — not as a standalone weight-loss intervention. Candidates typically have addressable hormonal patterns (low testosterone, suppressed thyroid, declining estradiol, elevated cortisol) already being treated, with body composition that has plateaued despite those upstream interventions. AOD-9604 is layered for adipose-tissue effect, not used as a first-line approach.
Realistic expectation: a modest lipolytic adjunct effect alongside hormone optimization and lifestyle protocols — not pharmaceutical-scale weight loss. Patients expecting GLP-1-class results from AOD-9604 will be disappointed; the magnitude of effect documented in clinical trials was modest. AOD-9604's role is supportive, not central. We discuss realistic expectations with every candidate before any prescription is written.
Patients with active malignancy. Pregnant or breastfeeding patients. Patients with severe untreated metabolic disease, untreated hypothyroidism, or untreated diabetes — those conditions are addressed first. Patients seeking AOD-9604 as a primary weight-loss intervention without supporting clinical context. We do not prescribe AOD-9604 as a standalone weight-loss solution; it is a layered adjunct only.
Upload existing bloodwork. Our clinical team reads it through the CLARITY framework to identify which upstream drivers are actually addressable. Free.
Get Your Free Lab Review →One consultation. Your biomarkers and clinical context map the protocol.
Book Your Consultation